August 11, 2025
Willkie is representing CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, in its acquisition of Melinta Therapeutics LLC, a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, for $300 million.
On August 7, CorMedix announced that it agreed to acquire Melinta, creating a diversified specialty company with a strong presence in acute care settings. Under the agreement, the selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN® and REZZAYO™.
The $260 million cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing. Willkie is also advising CorMedix on the debt financing for the acquisition.
The Willkie deal team is led by partners Jared Fertman and Andrew Marmer and includes associates Theodore Witt, Autri Saha, William Sobel, Jerolynn Liu and Emma Danziger and law clerk Akarshana Premanand. The team advising on the convertible note offering is led by partner Sean Ewen with associates Marissa Dressor and Qingqing (Chelsea) Zheng.
On August 7, CorMedix announced that it agreed to acquire Melinta, creating a diversified specialty company with a strong presence in acute care settings. Under the agreement, the selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN® and REZZAYO™.
The $260 million cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing. Willkie is also advising CorMedix on the debt financing for the acquisition.
The Willkie deal team is led by partners Jared Fertman and Andrew Marmer and includes associates Theodore Witt, Autri Saha, William Sobel, Jerolynn Liu and Emma Danziger and law clerk Akarshana Premanand. The team advising on the convertible note offering is led by partner Sean Ewen with associates Marissa Dressor and Qingqing (Chelsea) Zheng.
